Cardlytics (CDLX) Cash & Equivalents (2016 - 2026)

Cardlytics has reported Cash & Equivalents for 11 years, with the latest figure at $35.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 31.46% year-over-year to $35.7 million; the trailing twelve-month figure through Mar 2026 stood at $35.7 million (down 31.46% YoY), and the FY2025 full-year result was $48.7 million, down 25.73% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $35.7 million, down from $48.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $208.3 million in Q1 2022, with the low at $35.7 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $92.2 million across 5 years, with a median of $90.1 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 66.05% — and 2024, when it decreased 22.61%.
• Cardlytics' Cash & Equivalents stood at $121.9 million in 2022, then slipped by 24.67% to $91.8 million in 2023, then retreated by 28.57% to $65.6 million in 2024, then slipped by 25.73% to $48.7 million in 2025, then retreated by 26.78% to $35.7 million in 2026.
• The last three Cash & Equivalents figures came in at $35.7 million (Q1 2026), $48.7 million (Q4 2025), and $44.0 million (Q3 2025), per Business Quant data.